Industry News
11 Nov 2026

ZEISS Secures Chinese Approval for Next-Generation PT LUNANA Phakic IOL, Signalling Global Refractive Expansion

ZEISS Secures Chinese Approval for Next-Generation PT LUNANA Phakic IOL, Signalling Global Refractive ExpansionZEISS has taken a significant step in expanding its refractive surgery portfolio with the National Medical Products Administration (NMPA) approval of the ZEISS PT LUNANA phakic intraocular lens (pIOL) in China. 

Unveiled at the 9th China International Import Expo (CIIE) in Shanghai on 9 November, the PT LUNANA represents the first product in ZEISS's new Phakic Technology (PT) family. For ophthalmologists and refractive surgeons, the development offers an early glimpse into the next generation of phakic IOLs, with plans for a global rollout following its domestic launch.

Notably, the PT LUNANA was developed and will be manufactured locally by Wuxi Carl Zeiss Vision Pro Medical Technology Co., Ltd, a joint venture embodying ZEISS's "In China, for Global" innovation strategy. 

Targeting complex refractive errors

For eyecare professionals, the PT LUNANA offers a compelling alternative for patients who are not ideal candidates for laser vision correction, such as those with thin corneas or high myopia. 

The next-generation aspheric pIOL features ZEISS’s AQUAFLEX hydrophilic polymer material and boasts a highly customisable fitting profile to accommodate a wide range of myopia levels. 

"Each patient's eyes are unique, making precise, individualised fitting essential for phakic IOLs," noted Professor Wang Xiaoying, Chief Physician at the Eye and ENT Hospital of Fudan University in Shanghai. She highlighted that the lens offers a considered selection of seven lens sizes and 0.25-dioptre increments, "enabling physicians with greater choice when selecting a lens for individual patient needs."

Professor Zhou Xingtao, President of the Eye and ENT Hospital of Fudan University, added that the debut of the lens will allow patients to benefit from the innovation firsthand while providing ophthalmologists the opportunity to "gain valuable clinical experience early on and strengthen their influence in cutting-edge academic research."

A market driven by staggering myopia rates

ZEISS’s strategic focus on the Chinese market is underpinned by immense public health data. China is home to an estimated 600 million people with myopia. Recent systematic reviews indicate that 67.2 per cent of adolescents aged 15 to 19 have myopia, with 9.5 per cent classified as high myopia. 

As these younger demographics enter adulthood, the demand for individualised refractive-care pathways is accelerating. Furthermore, China's Work Plan for Accelerating the Provision of High-Quality and Efficient Eye Health Services (2026-2030) calls for increased coverage of effective refractive error correction, positioning phakic IOL surgery, a procedure with over three decades of clinical validation, as a critical mainstream option.

"The strong momentum of the Chinese market is driving ZEISS's 'In China, for Global' innovation strategy," said Martin Fischer, President and CEO of ZEISS Greater China. 

Andreas Völker, Head of the Ophthalmology Strategic Business Unit at ZEISS Medical Technology, noted that the approval "represents more than a product milestone; it underscores our ambition to innovate in China and help shape a future where more people have access to advanced solutions for myopia."

What this means for the global market

While the immediate focus is domestic commercialisation in China slated for 2027, the global eyecare community will not have to wait long to see the technology. 

Michael Achtelik, Global Head of the Refractive Lasers Business Sector at ZEISS Medical Technology, confirmed that the NMPA approval is "an important step in our journey to bring the ZEISS phakic IOL portfolio to ophthalmic customers worldwide." He emphasised that combining ZEISS’s global expertise in precision optics with local manufacturing capabilities will strengthen their ability to deliver personalised solutions globally.

For Australian practice owners and refractive surgeons, the impending global rollout of the PT LUNANA signals that ZEISS is heavily investing in the phakic IOL space. The lens will slot into ZEISS's broader lifetime myopia management ecosystem, sitting alongside offerings like Myocare lenses for children, Ortho-K lenses, and the SMILE pro laser platform, ensuring that clinics will soon have a new, highly customisable tool for managing complex refractive errors.